This test detects 346 genes, including HRR pathway genes. The content involves targeted therapy, immunotherapy, chemotherapy and hereditary risk assessment, and provides comprehensive medication reference for prostate cancer patients. Features of Individualized Medication Guidance for Prostate Cancer Diagnosis Targeted therapy-Including SNV, InDel, CNV and gene rearrangement, comprehensively guide targeted drug use. Immunotherapy-Detect TMB and MSI indicators, as well as positive and negative immune-related genes, provide information to guide immunosuppressive therapy. Chemotherapy- Detect chemotherapeutic drug loci associated with prostate cancer, suggesting sensitivity and toxic side effects of chemotherapeutic drugs. Hereditary risk assessment- Covering HRR pathway genes, suggesting pathogenic and suspected pathogenic variants, guiding PARP inhibitor therapy, and suggesting genetic risk based on family tumor history and other information. Applicable Population of Individualized Medication Guidance for Prostate Cancer Prognosis,

rostate PAs an ivd in vitro diagnostic